Boehringer Ingelheim
 |
|
| Type | Private |
|---|---|
| Industry | Pharmaceuticals |
| Founded | Germany (1885) |
| Headquarters | Binger Str. 173, 55216 Ingelheim Germany |
| Key people | Andreas Barner, Chairman of the board Hubertus von Baumbach, board member Wolfram Carius, board member Engelbert Tjeenk Willink, board member |
| Products | Human Pharmaceuticals and Animal Health |
| Revenue |  €12.586 billion EUR (2010) |
| Operating income | €1.896 billion EUR (2010) |
| Net income | €888 million EUR (2010) |
| Employees | 42,224 (2010) |
| Website | http://www.boehringer-ingelheim.com |
C.H. Boehringer Sohn AG & Ko. KG is the parent company of Boehringer Ingelheim, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. The companies key assets of interest are: respiratory disease, cardiovascular disease, Parkinson's disease, HIV, thromboembolic disease and cerebrovascular disease. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations EFPIA. The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.[1]
Contents |
[edit] Fields of activity
The business areas consist of Human Pharmaceuticals and Animal Health. In 2010, 42,224 employees were in 145 affiliated companies worldwide, research and development (R&D) facilities were in seven sites and 20 production plants in 13 countries. Boehringer Ingelheim's Pharma Chemicals business has pioneered the commercial production of monomers and biodegradable polymers for more than 20 years.
[edit] History
History 1885: Albert Boehringer buys a small tartar factory in Ingelheim am Rhein. The doors open and work begins on August 1st. 1886: The factory commences production of tartaric acid for use in the food industry (e.g. in baking powder and carbonated beverages). 1893: Albert Boehringer renames the company C. H. Boehringer Sohn (CHBS) in honour of his father, Christoph Heinrich Boehringer. 1893: While experimenting with the production of citric acid, lactic acid is formed. Albert Boehringer develops this process, with the intention of producing lactic acid on a larger scale. 1895: Lactic acid is produced on an industrial scale. This becomes a commercial success and instates CHBS as a pioneer in the field of industrial applications of biotechnological processes. 1917: Professor Heinrich Wieland, chemist, future Nobel Prize winner and cousin of Albert Boehringer, initiates the foundation of the company’s research department. 1928: Albert Boehringer purchases Dr. Karl Thomae, a company based in Winnenden near Stuttgart. 1946: Dr. Karl Thomae GmbH is re-opened in Biberach an der Riss with a staff of 70 people. 1954: The company hires Fritz Fischer after he is released from jail. 1955: The Animal Health division is established as the company acquires Pfizer’s veterinary programme. 1971: The foreign subsidiary, Boehringer Ingelheim Pharmaceuticals, Inc is founded in Ridgefield, Connecticut (USA). This site is soon expanded, taking its place as the company’s North American research centre. 1985: This year sees the Institute for Molecular Pathology (IMP) established in Vienna; it opens in 1988. 1986: The biotechnological centre in Biberach begins production of biopharmaceuticals from cell cultures. 1998: The merging of Boehringer Ingelheim KG and Dr. Karl Thomae GmbH founds Boehringer Ingelheim Pharma KG. 2010: The company celebrates its 125th anniversary.
[edit] Collaborative research
In addition to internal research and development activities Boehringer Ingelheim is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[2][3] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[4]
[edit] Operational/development sites
The company's largest site and corporate headquarters is located in Ingelheim am Rhein near Mainz and Frankfurt, Germany. However, Boehringer Ingelheim is a globally-operating company, with 145 subsidiaries around the globe. Their main business regions are Europe, North America and Asia. The Research Institute of Molecular Pathology[5] in Vienna (Austria), founded in 1985, has had Boehringer Ingelheim as its main sponsor since 1993.
In December 2008, the Boehringer Ingelheim group of companies had 41,300 employees worldwide. Of these, about 30% worked in production, 39% in marketing and sales, and 16.5% in research and development. In 2005, the German magazine 'Capital' placed the company second in a 2005 list of Germany's best employers, and in the United Kingdom the company was placed 19th in The Sunday Times' 100 Best Companies To Work For. In 2006 the Science magazine (US) listed Boehringer Ingelheim as second place for top employers in the biotechnology and pharmaceutical industries.[5]
In 2010, the Boehringer Ingelheim group of companies had 42,224 employees worldwide. Of these, 12,647 worked in production, 16,543 in marketing and sales, and 7,093 in research and development. In Germany, Brazil, the Netherlands, and the United Kingdom, Boehringer Ingelheim received recognition as one of the best employers for the year 2009. In 2009 the English newspaper ‘Sunday Times’ placed the company in the list ‘Best Places to Work’. The ‘Workforce Diversity Magazine’ and the ‘Careers & the disABLED Magazine’ placed Boehringer Ingelheim as “A Top 50 Employer, Reader’s Choice: 2009”.
[edit] Key product lines
Aggrenox, Antistax, Bisolvon, Buscopan, Buscapina, CircoFLEX, Dulcolax, Duramune, Flomax, Metacam, Micardis + Micardis Plus, Mirapex, Mucosolvan, Mucoangin, Mobic, Spiriva, Pharmaton, Pradaxa, Resomer, Vetmedin, Viramune, Zantac, Twynsta.
[edit] See also
[edit] Notes
- ^ "Boehringer Ingelheim Logo: Design and History". FamousLogos.us. http://www.famouslogos.us/boehringer-ingelheim-logo. Retrieved 2011-08-18.
- ^ Mattes WB (2008), Public consortium efforts in toxicogenomics, Methods Mol Biol. 2008;460:221-38 [1]
- ^ "InnoMed PredTox Member Organizations". http://www.innomed-predtox.com/consortium/members/. Retrieved 2008-08-25.
- ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. http://www.eurosfaire.prd.fr/7pc/documents/1210683220_imi_1rst_call_topics.pdf. Retrieved 2008-08-25.
- ^ Gwynne, Peter (October 20, 2006), "TOP EMPLOYER SURVEY: It All Starts with Science",Science. Retrieved August 26, 2007.
[edit] External links
- Boehringer Ingelheim Corporate website
- Boehringer Ingelheim Vetmedica United States Animal Health website
- Boehringer Ingelheim German website
- Boehringer Ingelheim USA website
- News-Centre (for journalists)
- Social Media at Boehringer Ingelheim
- CHC Products
- Boehringer Ingelheim Italia
- Boehringer Ingelheim Argentina
- Boehringer Ingelheim (Canada) Ltd.
- Boehringer Ingelheim Brazil
- Boehringer Ingelheim Spain
- Boehringer Ingelheim Mexico
- Site Buscopan Brazil
- Boehringer Ingelheim UK
- Boehringer Ingelheim Japan
